Literature DB >> 16500745

Clinico-pathological and immunohistochemical characteristics associated to recurrence/regrowth of craniopharyngiomas.

Martha Lilia Tena-Suck1, Citlaltepetl Salinas-Lara, Rosa Isela Arce-Arellano, Daniel Rembao-Bojórquez, Daniela Morales-Espinosa, Julio Sotelo, Oscar Arrieta.   

Abstract

BACKGROUND: Craniopharyngioma is a rare, benign epithelial brain tumor of the suprasellar region with a high rate of recurrence. Clinical and histopathological features that might be predictors of recurrence/regrowth have not been clearly delineated.
METHODS: We compared recurrence/regrowth of the tumors with the clinico-pathological characteristics, vascular density, cell proliferation index, and immunohistochemical profile (cytokeratins, epithelial membrane antigen [EMA], carcinoembrionary antigen [CEA], and laminin) of 47 patients with craniopharyngioma followed for more than 5 years.
RESULTS: Tumors were adamantinomatous in 42 cases (89%) and papillary squamous in 5 cases (11%). Immunoreactivity for cytokeratin 8/18/19 was positive in 64%; cytokeratin 5 in 42%; laminin 8 in 62%; and CEA in 21%. The cell proliferation index and vascular density were greater in adamantinomatous than in papillary tumors (22+/-6 versus 17+/-3, p=0.05; and 21+/-3 versus 17+/-3, p=0.037, respectively); they were neither related to recurrence nor to regrowth. No significant differences were found between adamantinomatous and papillary tumors regarding the presence of cytokeratin, laminin, CEA or glial fibrillary acidic protein (GFAP). Recurrence rate at 5 years was 59%. No relation was found between recurrence and adjuvant radiotherapy (AR). Residual tumor after surgery, whorl-like arrays (p=0.04) and immunoreactivity for p53 (p=0.022) were significantly related to recurrence/regrowth.
CONCLUSIONS: Residual tumor after surgery, immunoreactivity to p53 and presence of whorl-like arrays are associated to recurrence/regrowth of craniopharyngioma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16500745     DOI: 10.1016/j.clineuro.2006.01.007

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  13 in total

1.  Craniopharyngiomas in children: how radical should the surgeon be?

Authors:  Juraj Steňo; Ivan Bízik; Andrej Steňo; Viktor Matejčík
Journal:  Childs Nerv Syst       Date:  2010-11-12       Impact factor: 1.475

2.  Management of pediatric craniopharyngioma: 10-year experience from high-flow center.

Authors:  Abd El Rahman Enayet; Mostafa M E Atteya; Hala Taha; Mohamed Saad Zaghloul; Amal Refaat; Eslam Maher; Amal Abdelaziz; Mohamed A El Beltagy
Journal:  Childs Nerv Syst       Date:  2020-07-26       Impact factor: 1.475

Review 3.  Can tissue biomarkers reliably predict the biological behavior of craniopharyngiomas? A comprehensive overview.

Authors:  Ruth Prieto; José M Pascual
Journal:  Pituitary       Date:  2018-08       Impact factor: 4.107

4.  Excision of pediatric craniopharyngioma: pattern of recurrence in 35 patients at a tertiary care hospital in Saudi Arabia.

Authors:  Essam Al Shail; Ahmad Al-Shenkiti; Mohammad T Alotaibi; Khawar Siddiqui; Amani Al-Kofide
Journal:  Childs Nerv Syst       Date:  2019-09-03       Impact factor: 1.475

Review 5.  Histopathological and molecular predictors of growth patterns and recurrence in craniopharyngiomas: a systematic review.

Authors:  Josephine R Coury; Brittany N Davis; Christoforos P Koumas; Giovanna S Manzano; Amir R Dehdashti
Journal:  Neurosurg Rev       Date:  2018-04-17       Impact factor: 3.042

6.  Treatment of Cystic Craniopharyngiomas: An Update.

Authors:  Federico Bianchi; Alberto Benato; Luca Massimi
Journal:  Adv Tech Stand Neurosurg       Date:  2022

7.  All-trans retinoic acid inhibits craniopharyngioma cell growth: study on an explant cell model.

Authors:  Qiang Li; Chao You; Liangxue Zhou; Xiutian Sima; Zhiyong Liu; Hao Liu; Jianguo Xu
Journal:  J Neurooncol       Date:  2013-02-20       Impact factor: 4.130

8.  Endocrinologic, neurologic, and visual morbidity after treatment for craniopharyngioma.

Authors:  Michael E Sughrue; Isaac Yang; Ari J Kane; Shanna Fang; Aaron J Clark; Derrick Aranda; Igor J Barani; Andrew T Parsa
Journal:  J Neurooncol       Date:  2010-06-10       Impact factor: 4.130

Review 9.  Association of histological subtype with risk of recurrence in craniopharyngioma patients: a systematic review and meta-analysis.

Authors:  Jie Wu; Xiao Wu; You Qing Yang; Han Ding; Le Yang; You Yuan Bao; Lin Zhou; Chen Xing Yang; Tao Hong
Journal:  Neurosurg Rev       Date:  2021-06-22       Impact factor: 2.800

10.  Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.

Authors:  John R Apps; Gabriela Carreno; Jose Mario Gonzalez-Meljem; Scott Haston; Romain Guiho; Julie E Cooper; Saba Manshaei; Nital Jani; Annett Hölsken; Benedetta Pettorini; Robert J Beynon; Deborah M Simpson; Helen C Fraser; Ying Hong; Shirleen Hallang; Thomas J Stone; Alex Virasami; Andrew M Donson; David Jones; Kristian Aquilina; Helen Spoudeas; Abhijit R Joshi; Richard Grundy; Lisa C D Storer; Márta Korbonits; David A Hilton; Kyoko Tossell; Selvam Thavaraj; Mark A Ungless; Jesus Gil; Rolf Buslei; Todd Hankinson; Darren Hargrave; Colin Goding; Cynthia L Andoniadou; Paul Brogan; Thomas S Jacques; Hywel J Williams; Juan Pedro Martinez-Barbera
Journal:  Acta Neuropathol       Date:  2018-03-14       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.